Pain Therapeutics 2005 Explains Just What the Cox-II Crisis Means for the Future of Pain Management

Research and Markets has announced the addition of Pain Therapeutics 2005:Market Dynamics and Outlook to their offering.

Dublin (PRWEB) March 2, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c33714) has announced the addition of Pain Therapeutics 2005:Market Dynamics and Outlook to their offering.

Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.

About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value reaching nearly $23 billion in 2004.

In this new report, key pain management therapeutics such as Cox-II inhibitors, opioids, triptans, anticonvulsants and traditional NSAIDs are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain.

The dynamics of this market have been altered greatly over the past year. The troubles surrounding the multi-billion dollar Cox-II class has created a void in the marketplace. Pain Therapeutics 2005 explains just what the Cox-II crisis means for the future of pain management and what kinds of opportunities their failure may present for other classes of pain management medications.

Pain Therapeutics 2005 also analyzes the markets and provides forecasts for:

- the fast-growing anticonvulsant class

- migraine therapies

- traditional NSAIDs

- and opioids.

Company Profiles:

Abbott Laboratories

AlgoRx Pharmaceuticals

Altea Therapeutics

Ardent Pharmaceuticals

AstraZeneca

Cephalon

Elan Pharmaceuticals

Endo Pharmacuticals

EpiCept

GlaxoSmithKline

Indevus Pharmaceuticals

Innovative Drug Delivery Systems

Johnson & Johnson

Metaphore Pharmaceuticals

Nastech Pharmaceutical

NeurogesX

Novartis Pharmaceuticals

Pain Therapeutics

Pfizer

Purdue

Renovis

SkyePharma

For more information visit http://www.researchandmarkets.com/reports/c33714

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###